GlobeNewswire: Incysus Therapeutics, Inc Contains the last 10 of 17 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T05:37:00ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2018/10/16/1621865/0/en/Incysus-Therapeutics-to-Present-at-the-2018-Bio-Investor-Forum.html?f=22&fvtc=4&fvtv=32214Incysus Therapeutics to Present at the 2018 Bio Investor Forum2018-10-16T12:00:00Z<![CDATA[NEW YORK, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the treatment of cancers, announced today that the Company will present at the 2018 BIO Investor Forum being held in San Francisco, CA on October 17-18. William Ho, President and Chief Executive Officer of Incysus, will present a company overview.]]>https://www.globenewswire.com/news-release/2018/08/16/1552909/0/en/Lawrence-Lamb-Ph-D-Incysus-Therapeutics-Scientific-Co-Founder-to-Present-at-10th-Annual-Bioprocessing-Summit.html?f=22&fvtc=4&fvtv=32214Lawrence Lamb, Ph.D. Incysus Therapeutics Scientific Co-Founder to Present at 10th Annual Bioprocessing Summit2018-08-16T12:00:00Z<![CDATA[NEW YORK, Aug. 16, 2018 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc., a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the treatment of cancers, announced today that Lawrence S. Lamb, Ph.D., Professor of Medicine and Director of the Cell Therapy Laboratory at the University of Alabama at Birmingham (UAB) and Scientific Co-Founder of Incysus, will present at a scientific symposium today, on Thursday, August 16, 2018 during the 10th Annual Bioprocessing Summit, in Boston, Massachusetts.]]>https://www.globenewswire.com/news-release/2018/06/08/1518953/0/en/Incysus-Therapeutics-Scientific-Co-Founder-Lawrence-Lamb-PhD-to-Present-at-8th-International-Gamma-Delta-T-Cell-Conference.html?f=22&fvtc=4&fvtv=32214Incysus Therapeutics Scientific Co-Founder Lawrence Lamb, PhD to Present at 8th International Gamma-Delta T Cell Conference2018-06-08T12:00:00Z<![CDATA[Symposium Title: “Targeting of chemotherapy-induced NKG2DL by localized repetitive γδ T cell infusions: a rational therapeutic design for elimination of minimal residual primary high grade gliomas”]]>https://www.globenewswire.com/news-release/2018/05/22/1509964/0/en/Incysus-Moves-Its-Corporate-Domicile-to-Delaware.html?f=22&fvtc=4&fvtv=32214Incysus Moves Its Corporate Domicile to Delaware2018-05-22T12:00:00Z<![CDATA[NEW YORK, May 22, 2018 (GLOBE NEWSWIRE) -- Incysus, Ltd., a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the treatment of cancers, announced that effective May 7, 2018 it had moved its corporate domicile from Bermuda to Delaware and changed its name to “Incysus Therapeutics, Inc.”]]>https://www.globenewswire.com/news-release/2018/05/17/1508090/0/en/Incysus-Therapeutics-Scientific-Co-Founder-Lawrence-Lamb-Ph-D-and-Marcela-Maus-M-D-Ph-D-to-Co-Chair-Gene-Therapy-Symposium-During-2018-ASGCT-Meeting.html?f=22&fvtc=4&fvtv=32214Incysus Therapeutics’ Scientific Co-Founder Lawrence Lamb, Ph.D. and Marcela Maus, M.D., Ph.D. to Co-Chair Gene Therapy Symposium During 2018 ASGCT Meeting2018-05-17T12:00:00Z<![CDATA[Symposium Title: “Tipping Point: Gene Therapy Entering the Market”]]>https://www.globenewswire.com/news-release/2018/05/14/1501808/0/en/Incysus-Announces-Appointment-of-Joy-Bessenger-as-Senior-Vice-President-Finance-and-Strategy.html?f=22&fvtc=4&fvtv=32214Incysus Announces Appointment of Joy Bessenger as Senior Vice President, Finance and Strategy2018-05-14T14:00:00Z<![CDATA[NEW YORK, May 14, 2018 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc., a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the treatment of cancers, announced today that Joy E. Bessenger has been appointed Senior Vice President, Finance and Strategy.]]>https://www.globenewswire.com/news-release/2018/03/21/1443528/0/en/Incysus-to-Present-at-BioCentury-Future-Leaders-Conference.html?f=22&fvtc=4&fvtv=32214Incysus to Present at BioCentury Future Leaders Conference2018-03-21T12:00:00Z<![CDATA[NEW YORK, March 21, 2018 (GLOBE NEWSWIRE) -- Incysus, Ltd., a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the treatment of cancers, announced today that William Ho, Chief Executive Officer, will be presenting at the 25th Annual BioCentury Future Leaders Conference on March 23, 2018 at 2:30pm EDT at the Millennium Broadway Hotel and Conference Center in New York.]]>https://www.globenewswire.com/news-release/2018/03/20/1442691/0/en/Incysus-to-Present-Scientific-Overview-at-the-2018-CAR-T-Congress-USA-Meeting.html?f=22&fvtc=4&fvtv=32214Incysus to Present Scientific Overview at the 2018 CAR-T Congress USA Meeting2018-03-20T12:00:00Z<![CDATA[Dr. Lawrence Lamb to Present Adoptive Gamma-Delta T Cell Immunotherapy as a Strategy for Eliminating Residual Malignancy Dr. Lawrence Lamb to Present Adoptive Gamma-Delta T Cell Immunotherapy as a Strategy for Eliminating Residual Malignancy]]>https://www.globenewswire.com/news-release/2018/02/13/1340182/0/en/Incysus-Presents-Positive-Data-on-Drug-Resistant-Immunotherapy-for-Glioblastoma-at-AACR-CNS-Immunotherapy-Conference.html?f=22&fvtc=4&fvtv=32214Incysus Presents Positive Data on Drug-Resistant Immunotherapy for Glioblastoma at AACR CNS Immunotherapy Conference2018-02-13T21:00:00Z<![CDATA[-- Presentation at Plenary Session of the Immunobiology of Primary and Metastatic CNS Cancer: Multidisciplinary Science to Advance Cancer Immunotherapy -- -- Presentation at Plenary Session of the Immunobiology of Primary and Metastatic CNS Cancer: Multidisciplinary Science to Advance Cancer Immunotherapy --]]>https://www.globenewswire.com/news-release/2018/01/09/1285898/0/en/Incysus-Submits-Second-Investigational-New-Drug-Application-for-Gamma-Delta-T-Cell-Immunotherapy-Candidate.html?f=22&fvtc=4&fvtv=32214Incysus Submits Second Investigational New Drug Application for Gamma-Delta T Cell Immunotherapy Candidate2018-01-09T12:30:00Z<![CDATA[IND to support Phase 1 safety and activity study of Drug Resistant Immunotherapy for the treatment of glioblastoma IND to support Phase 1 safety and activity study of Drug Resistant Immunotherapy for the treatment of glioblastoma]]>